These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38832203)

  • 1. Cardiotoxicity in Cancer Patients: The Prevalence, Risk Factors, and Cardioprotective Measures in a Cancer Centre in Saudi Arabia.
    Badheeb AM; Alhosni Y; Alshahrani M; Asery TA; Al Nasher SM; Seada IA; Nasher AM; Alotaibi BA; Alsaaed E; Alsalem AM; Abu Bakar A; Alselwi W; Ahmed F; Alyami NH; Bin Dahman L; Badheeb M; Obied HY
    Cureus; 2024 May; 16(5):e59608. PubMed ID: 38832203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia.
    Badheeb AM; Ahmed F; Alzahrani HA; Badheeb MA; Obied HY; Seada IA
    Cureus; 2023 Jul; 15(7):e41287. PubMed ID: 37533611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.
    Kosalka P; Johnson C; Turek M; Sulpher J; Law A; Botros J; Dent S; Aseyev O
    Curr Oncol; 2019 Jun; 26(3):e314-e321. PubMed ID: 31285674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.
    Jawa Z; Perez RM; Garlie L; Singh M; Qamar R; Khandheria BK; Jahangir A; Shi Y
    Medicine (Baltimore); 2016 Nov; 95(44):e5195. PubMed ID: 27858859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Care During the COVID-19 Pandemic: A Retrospective Study From a Najran Oncology Center.
    Badheeb AM; Musallam SH; Alyami AY; Almakrami AH; Al-Swedan AD; Ahmed F; Badheeb M; Aedh AI; Obied HY; Seada IA; Alyami NH; Elhadi M; Aman AA; Alkarak S; Haridi HK
    Cureus; 2024 Jun; 16(6):e63252. PubMed ID: 39070488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Depression and Anxiety Symptoms Among Patients With Cancer in Najran, Saudi Arabia.
    Ghowinam MA; Albokhari AA; Badheeb AM; Lamlom M; Alwadai M; Hamza A; Aladalah A
    Cureus; 2024 Feb; 16(2):e54349. PubMed ID: 38500908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
    Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
    PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
    Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
    Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
    JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
    PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center.
    Al-Saleh K; Abdel-Warith A; Alghamdi M; Aldiab A; Ali A; Alsaeed EF; Abozeed WN; Abdel-Aziz N
    Mol Clin Oncol; 2022 Apr; 16(4):78. PubMed ID: 35251629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
    Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Five-Year Retrospective Study in 10 Centers.
    Gerodias FR; Tan MK; De Guzman A; Bernan A; Locnen SA; Apostol-Alday A; Ybanez EJ; Magno JD; Lim A; Junia A; Mambulao R; Cosare-San Pedro J; Lucero J; Quijano Z; Apurillo J; Uson AJ; Lim JL; Inso CA; Agoncillo-Infante A; Bongcawil RY; Fernando GY; Ramos-Manalaysay AM; Arellano-Simon FA; Ilagan-Cargullo EM; Bago-Azares MJ; Baterna J; Tapispisan JA; Masadao-Rodriguez NM; Tarranza JL; Lista LS; Gumapon JK
    Cardiol Res; 2022 Dec; 13(6):380-392. PubMed ID: 36660064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution's experience.
    Aldiab A
    J Saudi Heart Assoc; 2010 Jul; 22(3):133-6. PubMed ID: 23960606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer.
    Umadat G; Ray J; Cornell L; Pillai D; Gharacholou SM
    Am J Cardiol; 2023 Feb; 188():68-79. PubMed ID: 36473307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.